The Indian Pharmaceutical Tradition

India is responsible for roughly 20% of the world's supply of generic medicines by volume (WHO essential medicines program). During the COVID-19 pandemic, Indian manufacturers produced more than 60% of the global vaccine supply. More than 200 countries receive medicines from Indian pharmaceutical companies — from low-income nations to G7 economies alike.

This scale is the foundation of Indian generic pricing. A single Indian facility can produce hundreds of millions of tablets per year, spreading fixed costs across enormous volumes. The per-unit cost drops accordingly.

A brand-name medication reflects two decades of pre-launch research, clinical trials, marketing, and regulatory filings — investments that can exceed one billion USD. When a patent expires, any manufacturer may produce the same molecule, skipping the research and marketing costs entirely. The result is a chemically identical medicine, priced to reflect only the cost of manufacturing, quality assurance, and distribution.

• Patent expiration enables lawful generic production
• Economies of scale across thousands of manufacturing facilities
• Lower labor and operational costs within India
• No direct-to-consumer marketing expenses
• Regulatory compliance under WHO-GMP, EU-GMP, and USFDA standards

The largest Indian manufacturers — including those whose products appear in our catalog — operate facilities approved by the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization, and the regulatory bodies of Japan, Australia, Canada, and the United Kingdom. India's own regulator, the Central Drugs Standard Control Organisation (CDSCO), oversees domestic manufacturing licensing. A medicine produced in a WHO-GMP approved Indian facility is chemically and pharmacologically identical to the same molecule produced elsewhere.

We source exclusively from manufacturers whose facilities meet or exceed these standards. Every product sold by LiberaCure comes from a licensed pharmaceutical manufacturer in India.

For individuals in countries where brand-name medications are prohibitively expensive, unavailable, or reserved for those with comprehensive insurance, Indian generics represent a practical alternative. They are the same molecules, manufactured to the same standards, at prices determined by production cost rather than patent rent.

LiberaCure exists to make that alternative accessible, with transparent sourcing and respectful handling of personal and medical privacy.